These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 36869170)

  • 1. Alternative Methods for Therapeutic Drug Monitoring and Dose Adjustment of Tuberculosis Treatment in Clinical Settings: A Systematic Review.
    Rao PS; Modi N; Nguyen NT; Vu DH; Xie YL; Gandhi M; Gerona R; Metcalfe J; Heysell SK; Alffenaar JC
    Clin Pharmacokinet; 2023 Mar; 62(3):375-398. PubMed ID: 36869170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic Review of Salivary Versus Blood Concentrations of Antituberculosis Drugs and Their Potential for Salivary Therapeutic Drug Monitoring.
    van den Elsen SHJ; Oostenbrink LM; Heysell SK; Hira D; Touw DJ; Akkerman OW; Bolhuis MS; Alffenaar JC
    Ther Drug Monit; 2018 Feb; 40(1):17-37. PubMed ID: 29120971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis.
    Zuur MA; Bolhuis MS; Anthony R; den Hertog A; van der Laan T; Wilffert B; de Lange W; van Soolingen D; Alffenaar JW
    Expert Opin Drug Metab Toxicol; 2016 May; 12(5):509-21. PubMed ID: 26950189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug monitoring in the treatment of tuberculosis: an update.
    Alsultan A; Peloquin CA
    Drugs; 2014 Jun; 74(8):839-54. PubMed ID: 24846578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding pharmacokinetics to improve tuberculosis treatment outcome.
    Reynolds J; Heysell SK
    Expert Opin Drug Metab Toxicol; 2014 Jun; 10(6):813-23. PubMed ID: 24597717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children.
    Martial LC; Kerkhoff J; Martinez N; Rodríguez M; Coronel R; Molinas G; Roman M; Gomez R; Aguirre S; Jongedijk E; Huisman J; Touw DJ; Pérez D; Chaparro G; Gonzalez F; Aarnoutse RE; Alffenaar JW; Magis-Escurra C
    Int J Antimicrob Agents; 2018 Jul; 52(1):109-113. PubMed ID: 29751121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs.
    Kuhlin J; Sturkenboom MGG; Ghimire S; Margineanu I; van den Elsen SHJ; Simbar N; Akkerman OW; Jongedijk EM; Koster RA; Bruchfeld J; Touw DJ; Alffenaar JC
    Clin Mass Spectrom; 2019 Sep; 14 Pt A():34-45. PubMed ID: 34934812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LC-MS/MS method for simultaneous quantification of the first-line anti-tuberculosis drugs and six primary metabolites in patient plasma: Implications for therapeutic drug monitoring.
    Kivrane A; Grinberga S; Sevostjanovs E; Igumnova V; Pole I; Viksna A; Bandere D; Krams A; Cirule A; Pugovics O; Ranka R
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Nov; 1185():122986. PubMed ID: 34688197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of rifapentine, a potent antituberculosis drug, from dried blood spot samples using liquid chromatographic-tandem mass spectrometric analysis.
    Parsons TL; Marzinke MA; Hoang T; Bliven-Sizemore E; Weiner M; Mac Kenzie WR; Dorman SE; Dooley KE
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6747-57. PubMed ID: 25182637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dried blood spots: a new tool for tuberculosis treatment optimization.
    Vu DH; Alffenaar JW; Edelbroek PM; Brouwers JR; Uges DR
    Curr Pharm Des; 2011; 17(27):2931-9. PubMed ID: 21834763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
    Verbeeck RK; Günther G; Kibuule D; Hunter C; Rennie TW
    Eur J Clin Pharmacol; 2016 Aug; 72(8):905-16. PubMed ID: 27305904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?
    Motta I; Calcagno A; Bonora S
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):59-82. PubMed ID: 29226732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Point-of-Care International Normalized Ratio (INR) Monitoring Devices for Patients on Long-term Oral Anticoagulation Therapy: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(12):1-114. PubMed ID: 23074516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urine colorimetry for therapeutic drug monitoring of pyrazinamide during tuberculosis treatment.
    Zentner I; Modongo C; Zetola NM; Pasipanodya JG; Srivastava S; Heysell SK; Mpagama S; Schlect HP; Gumbo T; Bisson GP; Vinnard C
    Int J Infect Dis; 2018 Mar; 68():18-23. PubMed ID: 29253711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic accuracy of a liquid chromatography-tandem mass spectrometry assay in small hair samples for rifampin-resistant tuberculosis drug concentrations in a routine care setting.
    Metcalfe J; Bacchetti P; Esmail A; Reckers A; Aguilar D; Wen A; Huo S; Muyindike WR; Hahn JA; Dheda K; Gandhi M; Gerona R
    BMC Infect Dis; 2021 Jan; 21(1):99. PubMed ID: 33482745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
    Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
    Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic drug monitoring in antituberculosis chemotherapy: clinical perspectives.
    Yew WW
    Clin Chim Acta; 2001 Nov; 313(1-2):31-6. PubMed ID: 11694236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic drug monitoring in the treatment of tuberculosis.
    Peloquin CA
    Drugs; 2002; 62(15):2169-83. PubMed ID: 12381217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.